Kymera Therapeutics, Inc. (KYMR) vs Madrigal Pharmaceuticals, Inc. (MDGL)
- Kymera Therapeutics, Inc. KYMR 104.78 −3.11%
- Madrigal Pharmaceuticals, Inc. MDGL 449.74 −2.19%
Kymera Therapeutics, Inc. and Madrigal Pharmaceuticals, Inc. are both Biotechnology companies. Madrigal Pharmaceuticals, Inc. is the larger, with a market value of $10.6B against $9.0B — 1.2× the size. Madrigal Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 149.0% against 134.8%. Madrigal Pharmaceuticals, Inc. has the higher net margin (−25.3% vs −285.3%) and the lower return on invested capital (−787.3% vs −26.7%). Across the 17 metrics below, Madrigal Pharmaceuticals, Inc. leads on 10 and Kymera Therapeutics, Inc. on 7.
Valuation
Profitability
| Metric | KYMR | MDGL | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 91.48% | 65.16% |
| Operating margin | (333.50%) | (25.13%) | 0.00% |
| Net margin | (285.33%) | (25.32%) | 0.00% |
| Free cash flow margin | (226.62%) | (16.07%) | 0.00% |
| Return on equity | (24.15%) | (53.31%) | (56.36%) |
| Return on assets | (21.58%) | (28.77%) | (48.04%) |
| Return on invested capital | (26.72%) | (787.33%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack